Treatment Clinical Trials for Gastrointestinal Neuroendocrine Tumor G1
Clinical trials are research studies that involve people. The clinical trials on this list are for gastrointestinal neuroendocrine tumor g1 treatment. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Protocol PEN-221-001 is an open-label, multicenter Phase 1 / 2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung.
Location: 6 locations
Ribociclib and Everolimus in Treating Patients with Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
This phase II trial studies how well ribociclib and everolimus work in treating patients with well differentiated neuroendocrine tumors of foregut origin that have spread to other parts of the body and usually cannot be cured or controlled with treatment. Ribociclib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 6 locations
Cisplatin or Carboplatin and Etoposide With or Without Vandetanib in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer or High-Grade or Poorly Undifferentiated Neuroendocrine Cancer
This randomized phase II trial studies how well cisplatin or carboplatin and etoposide with or without vandetanib works in treating patients with previously untreated extensive stage small cell lung cancer or high-grade or poorly differentiated neuroendocrine cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cisplatin or carboplatin and etoposide is more effective with or without vandetanib in treating small cell lung cancer or neuroendocrine cancer.
Location: 2 locations
Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors Previously Treated with Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Location: Alliance for Clinical Trials in Oncology, Boston, Massachusetts
Regorafenib in Treating Patients with Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 3 locations